Drug firm Divis Laboratories today reported a 17.83% rise in consolidated net profit at Rs 231.47 crore for the quarter ended March 2015, mainly due to robust sales.
The company had posted a net profit of Rs 196.43 crore in the corresponding period of the previous fiscal, it said in a filing to the BSE.
Consolidated total income from operations also rose to Rs 820.70 crore for the quarter under review against Rs 750.21 crore a year ago.
For the full year 2014-15, the consolidated net profit rose to Rs 851.52 crore, from Rs 773.34 crore in the year-ago period.
Consolidated total income from operations grew to Rs 3,114.94 crore in 2014-15, from Rs 2,532.14 crore in 2013-14.
In a separate filing to BSE, Divis Laboratories said its Board has recommended a dividend of Rs 20 per share of Rs 2 face value for the year ended March 2015.
The company had posted a net profit of Rs 196.43 crore in the corresponding period of the previous fiscal, it said in a filing to the BSE.
Consolidated total income from operations also rose to Rs 820.70 crore for the quarter under review against Rs 750.21 crore a year ago.
For the full year 2014-15, the consolidated net profit rose to Rs 851.52 crore, from Rs 773.34 crore in the year-ago period.
Consolidated total income from operations grew to Rs 3,114.94 crore in 2014-15, from Rs 2,532.14 crore in 2013-14.
In a separate filing to BSE, Divis Laboratories said its Board has recommended a dividend of Rs 20 per share of Rs 2 face value for the year ended March 2015.
No comments:
Post a Comment